Pelthos Therapeutics Q4 EPS $(6.87) Misses $(4.13) Estimate, Sales $9.389M Beat $9.090M Estimate

Pelthos Therapeutics reported a Q4 loss of $(6.87) per share, missing the analyst estimate of $(4.13) by 66.34%, and representing a 115.36% increase in losses compared to $(3.19) per share from the same period last year. The company's quarterly sales were $9.389 million, surpassing the consensus estimate of $9.090 million by 3.29%.